 | | |
| |
|
| |
|
Appointments
|
|
Attending Pediatrician
|
|
Professor of Pediatrics
|
|
Professor of Pediatrics in Medicine
|
|
Professor of Pediatrics in Obstetrics and Gynecology
|
|
|
|
|
| |
Bussel, James Bruce
 (212) 746-3400  (212) 746-8609
- Patel VL, Schwartz J, Bussel JB. The Effect of Blocking the CD40-CD40ligand Pathway in Patients with Immune Thrombocytopenic Purpura. British Jounral of Haem, 2008; in press.
- Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, Wu A, Bussel JB, George JN, McMIllan R, Wysocki DK, Nichol JN. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 2008; in press.
- McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. American Journal of Hematology, 2008; 83(2): 150-4.
- Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, George JN, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet, 2008; 371: 395-403.
- Bussel JB, Hanna K, and the IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura (ITP). American Journal of Hematology, 2007; 82: 192-198.
- Scaradavou A, Cunningham-Rundles S, Ho JL, Folman C, Doo H, and Bussel JB. Superior effect of intravenous anti-D compared to IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. American Journal of Hematology, 2007; 82(5): 335-41.
- Giulino LB, Bussel JB, Neufeld EJ, and the Pediatric and Platelet Immunology Committees of the TMH clinical trial network. Treatment with Rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics, 2007; 150(4): 338-44.
- Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes, 2007; 5: 11.
- Page LK, Psaila B, Provan D, Hamilton JM, Jenkins JM, Elish AS, Lesser ML, Bussel JB. The ITP Bleeding Score (IBLS): Assessment of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP). British Journal of Haematology, 2007; 138(2): 245-8.
- Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, and Bussel JB. An antepartum treatment trial without early cordocentesis for ?standard risk? alloimmune thrombocytopenia: A randomized controlled trial. Obstetrics & Gynecology, 2007; 110 (2 Pt 1): 249-55.
- Herve M, Isnardi I, Ng YS, Bussel JB, Ochs HD, Cunningham-Rundles C, Meffre E. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med, 2007; 204(7): 1583-93.
- Tarantino MD, Bussel JB, Cines DB, McCrae KR, Gernsheimer T, Liebman HA, Wong WY, Kulkarni R, Grabowski E, McMillan R. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood, 2007; 109(12): 5527.
- Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multi-agent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 2007; 110(10): 3526-31.
- Bussel JB. Novel thrombopoietic agents: preliminary activity, potential benefit. J Support Oncol, 2007; 5 (4 Suppl 2): 63-84.
- Godeau B, Provan D, Bussel JB. Immune thrombocytopenic purpura in adults. Curr Opin Hematol, 2007; 14(5): 535-556.
- Bussel JB, Cines DB. Introduction: Immune thrombocytopenic purpura. Curr Opin Hematol, 2007; 14(5): 510.
- Andemariam B, Bussel J. New therapies for immune thrombocytopenic purpura. Curr Opin Hematol, 2007; 14(5): 427-31.
- Zhang L, Radigan L, Salzer U, Behrens T, Grimbacher B, Diaz G, Bussel JB, and Cunningham-Rundles C. Transmembrane Activator and Calcium-Modulating Cyclophilin Ligand Interactor Mutations in Common Variable Immunodeficiency: Clinical and Immunologic Outcomes in Heterozygotes. Journal of Allergy and Clinical Immunology, 2007; 120: 1178-85.
- Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag, an Oral Platelet Growth Factor, for the Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura. NEJM, 2007; 357(22): 2237-47.
- Cooper, N., Heddle, N.M., Haas, M. de, Reid, M.E., Lesser, M.L., Fleit, H.B., Woloski, B.M.R., and Bussel, J.B.: Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcRIIa and FcRIIIa polymorphisms. In press to British Journal of Haematology, 2004.
- Schwartz, J. and Bussel, J.B.: Anti-CD40L: biology and therapy in ITP. In press to Blood, 2004.
- Michel, M., Cooper, N., Jean, C., Frissora, C., and Bussel, J.B.: Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 103: 890 - 896.
- Michel, M., Novoa, M.V., and Bussel, J.B.: Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. British Journal of Haematology, 2003; 123:142-146
|
| |
|
| |
|
|
|
|
Back to Top